[L-DOPA/5HTP DECARBOXYLASE INHIBITORS: PHARMACOLOGICAL PROPERTIES. THERAPEUTIC INDICATIONS].
D000311:Adrenal Glands; D001833:Body Temperature Regulation; D050260:Carbohydrate Metabolism; D004231:Diuresis; D004296:Dopa Decarboxylase; D004791:Enzyme Inhibitors; D006943:Hyperglycemia; D007031:Hypothalamus; D007668:Kidney; D007980:Levodopa; D008099:Liver; D008660:Metabolism; D051379:Mice; D008995:Monoamine Oxidase; D010600:Pharmacology; D010902:Pituitary Gland; D051381:Rats; D012106:Research; D014667:Vasopressins
D004791:Enzyme Inhibitors; D014667:Vasopressins; D007980:Levodopa; D008995:Monoamine Oxidase; D004296:Dopa Decarboxylase
ADRENAL GLANDS; BODY TEMPERATURE REGULATION; CARBOHYDRATE METABOLISM; DIURESIS; DOPA DECARBOXYLASE; ENZYME INHIBITORS; EXPERIMENTAL LAB STUDY; HYPERGLYCEMIA; HYPOTHALAMUS; KIDNEY; LIVER; METABOLISM; MICE; MONOAMINE OXIDASE; PHARMACOLOGY; PITUITARY GLAND; RATS; VASOPRESSIN
LES INHIBITEURS DE LA L-DOPA/5HTP DECARBOXYLASE: PROPRI'ET'ES PHARMACOLOGIQUES. INDICATIONS TH'ERAPEUTIQUES.